| Advancing personalized cancer medicine in lung cancer. | |
| | |
MedLine Citation:
|
PMID: 23020726 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Although improvements in genomic technologies during the past decade have greatly advanced our understanding of the genomic alterations that contribute to lung cancer, and the disease has (to a degree) become a paradigm for individualized cancer treatment in solid tumors, additional challenges must be addressed before the goal of personalized cancer therapy can become a reality for lung cancer patients. |
| | |
Authors:
|
Laura E Macconaill |
Related Documents
:
|
20208286 - Perspectives on cancer screening among latino community members and internal medicine r... 23589546 - Existing and emerging technologies for tumor genomic profiling. 4820846 - Ecology of insect host-parasitoid communities. 22952676 - Fenton reaction induced cancer in wild type rats recapitulates genomic alterations obse... 17192846 - R115777 (zarnestra)/zoledronic acid (zometa) cooperation on inhibition of prostate canc... 21828236 - Circulating markers of interstitial lung disease and subsequent risk of lung cancer. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Archives of pathology & laboratory medicine Volume: 136 ISSN: 1543-2165 ISO Abbreviation: Arch. Pathol. Lab. Med. Publication Date: 2012 Oct |
Date Detail:
|
Created Date: 2012-10-01 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7607091 Medline TA: Arch Pathol Lab Med Country: United States |
Other Details:
|
Languages: eng Pagination: 1210-6 Citation Subset: AIM; IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Strategies for overcoming acquired resistance to epidermal growth factor receptor-targeted therapies...
Next Document: The separation of benign and malignant mesothelial proliferations.